| 1. |
《中國圍透析期慢性腎臟病管理規范》專家組. 中國圍透析期慢性腎臟病管理規范. 中華腎臟病雜志, 2021, 37(8): 690-704.
|
| 2. |
Ene-Iordache B, Perico N, Bikbov B, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health, 2016, 4(5): e307-e319.
|
| 3. |
Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. Adv Exp Med Biol, 2019, 1165: 3-15.
|
| 4. |
Le Pham NM, Ong TP, Vuong NL, et al. HLA types and their association with end-stage renal disease in Vietnamese patients: a cross-sectional study. Medicine (Baltimore), 2022, 101(48): e31856.
|
| 5. |
Sharma S, Sarnak MJ. Epidemiology: the global burden of reduced GFR: ESRD, CVD and mortality. Nat Rev Nephrol, 2017, 13(8): 447-448.
|
| 6. |
McCullough KP, Morgenstern H, Saran R, et al. Projecting ESRD incidence and prevalence in the United States through 2030. J Am Soc Nephrol, 2019, 30(1): 127-135.
|
| 7. |
Satyan S, Rocher LL. Impact of kidney transplantation on the progression of cardiovascular disease. Adv Chronic Kidney Dis, 2004, 11(3): 274-293.
|
| 8. |
Fejzi? E, Karamehi? J, Eminovi? I, et al. HLA genotyping in patients with end-stage renal disease waiting for cadaveric renal transplantation in Federation of Bosnia and Herzegovina. Open Access Maced J Med Sci, 2017, 5(1): 1-5.
|
| 9. |
Pan Q, Ma X, Chen H, et al. A single center study of protective and susceptible HLA alleles and haplotypes with end-stage renal disease in China. Hum Immunol, 2019, 80(11): 943-947.
|
| 10. |
U?ar F, S?nmez M, Ermanta? N, et al. The associations of HLA-A, -B, DRB1 alleles and haplotypes in Turkish lymphoma patients. Gene, 2016, 586(2): 263-267.
|
| 11. |
Edgerly CH, Weimer ET. The past, present, and future of HLA typing in transplantation. Methods Mol Biol, 2018, 1802: 1-10.
|
| 12. |
Noureen N, Zaidi N. Association between human leukocyte antigen (HLA) and end-stage renal disease (ESRD): a meta-analysis. PeerJ, 2023, 11: e14792.
|
| 13. |
潘芹芹, 馬驍, 樊甦, 等. 江蘇七地市漢族人群常見 HLA 單倍型多態性分析. 南京醫科大學學報(自然科學版), 2022, 42(10): 1387-1393.
|
| 14. |
Robson KJ, Ooi JD, Holdsworth SR, et al. HLA and kidney disease: from associations to mechanisms. Nat Rev Nephrol, 2018, 14(10): 636-655.
|
| 15. |
Hieu HT, Ha NT, Song LH, et al. Association of human leukocyte antigen haplotypes with end-stage renal disease in Vietnamese patients prior to first transplantation. Transplant Proc, 2019, 51(8): 2549-2554.
|
| 16. |
王蓉, 陳淑敏, 邵長峰, 等. 山東半島地區慢性腎衰竭患者 HLA-A、B、DRB1 等位基因多態性研究. 中國輸血雜志, 2022, 35(8): 832-836.
|
| 17. |
Noureen N, Shah FA, Lisec J, et al. Revisiting the association between human leukocyte antigen and end-stage renal disease. PLoS One, 2020, 15(9): e0238878.
|
| 18. |
Takemoto S, Port FK, Claas FH, et al. HLA matching for kidney transplantation. Hum Immunol, 2004, 65(12): 1489-1505.
|
| 19. |
Miles CD, Schaubel DE, Liu D, et al. The role of donor-recipient relationship in long-term outcomes of living donor renal transplantation. Transplantation, 2008, 85(10): 1483-1488.
|
| 20. |
李海濱, 孫煦勇, 裴永峰, 等. HLA 高分辨等位基因多態性及單倍體與廣西漢族終末期腎病易感性的相關性分析. 廣西科學, 2022, 29(3): 436-448.
|
| 21. |
裴永峰, 余梅, 黃惠妮, 等. 廣西壯族人群 HLA-A、-B、-C、-DRB1、-DQB1 高分辨等位基因多態性和單倍型的研究. 中國實驗血液學雜志, 2020, 28(4): 1397-1405.
|
| 22. |
Jiang Y, Li W, Lu J, et al. HLA-G +3142 C>G polymorphism and cancer risk: evidence from a meta-analysis and trial sequential analysis. Medicine (Baltimore), 2019, 98(25): e16067.
|
| 23. |
Ademovi?-Sazdani? D, Vojvodi? S. Human leukocyte antigen polymorphisms as susceptibility risk factors for end stage renal disease. Genetika, 2019, 51(2): 607-617.
|